Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 16Leukemia 14Breast Neoplasms 8Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Acute 6Neoplasms, Plasma Cell 5Multiple Myeloma 5Leukemia, Lymphocytic, Chronic, B-Cell 5Burkitt Lymphoma 5Neuroblastoma 4Myelodysplastic Syndromes 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myelomonocytic, Acute 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Hodgkin Disease 4Congenital Abnormalities 4Recurrence 3Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3

Interventions

Etoposide 23Cisplatin 15Carboplatin 13Irinotecan 12apatinib 11anlotinib 10durvalumab 7Topotecan 6toripalimab 4surufatinib 4sintilimab 4atezolizumab 4Temozolomide 4Drug Therapy 4tislelizumab 3lobaplatin 3camrelizumab 3Simvastatin 3Radiotherapy 3Ifosfamide 3Albumin-Bound Paclitaxel 3pembrolizumab 2pegylated granulocyte colony-stimulating factor 2olaparib 2niraparib 2isophosphamide mustard 2avelumab 2X-Rays 2Platinum 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Small Cell Lung Carcinoma × Peripheral Blood Stem Cell Transplantation × Clear all
NCT00003284 2014-01-06

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡